Research programme: cancer therapeutics - ActivX Biosciences
Alternative Names: AX13057Latest Information Update: 16 Jul 2016
At a glance
- Originator ActivX Biosciences
- Class Carbamates; Small molecules
- Mechanism of Action Hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 30 Mar 2011 Early research in Cancer in USA (unspecified route)
- 30 Mar 2011 Pharmacokinetics data from investigaitons in cancer presented at the 241st American Chemical Society National Meeting (241st-ACS-2011)